Lupin Launches Penicillamine Tablets USP

Global pharma major Lupin Limited (Lupin) today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.1022.55 as compared to the previous close of Rs. 1018.5. The total number of shares traded during the day was 193888 in over 5025 trades.

The stock hit an intraday high of Rs. 1034.6 and intraday low of 1011.55. The net turnover during the day was Rs. 198745030.

Source : Equity Bulls

Keywords